IMR Press / FBL / Volume 14 / Issue 13 / DOI: 10.2741/3579

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Innate immunity and hepatitis C virus: eluding the host cell defense
Show Less
1 Laboratory of Hepatitis and Related Emerging Agents, Division of Emerging and Transfusion-Transmitted Diseases, Office of Blood Research and Review, CBER FDA, 8800 Rockville Pike, HFM-310, NIH Building 29, 131,Bethesda, MD 20892

Academic Editor: Deborah Taylor

Front. Biosci. (Landmark Ed) 2009, 14(13), 4950–4961;
Published: 1 June 2009
(This article belongs to the Special Issue Innate immunity and protein synthesis)

Interferon-alpha (IFN-alpha) mono-therapy is largely ineffective for most of the hepatitis C virus (HCV)-infected patients that receive it. The addition of ribavirin to IFN therapy has increased the response rate dramatically. While many factors are implicated in determining the success rate for IFN therapy, viral genotype seems to play a crucial role. Examining differences in viral gene sequences has and will continue to advance our understanding as to how HCV and other viruses circumvent the IFN response. Here we review the different ways that HCV evades the immune response elicited by IFN.

Back to top